Zydus Lifesciences’ Empagliflozin/Linagliptin Approval Analyzed
Zydus Lifesciences has achieved a significant milestone: the U.S. Food and Drug Administration (FDA) has granted tentative approval for their new Empagliflozin and Linagliptin Tablets. This approval allows Zydus to produce a generic version of Glyxambi Tablets, which is used to help people manage type 2 diabetes.
Key Points
Here’s what’s important to know:
- Zydus gained FDA approval for Empagliflozin/Linagliptin tablets.
- This is a generic version of the Glyxambi medication.
- Tablets are made at Zydus’ facility in Ahmedabad, India.
- Glyxambi helps control blood sugar when combined with diet/exercise.
- Sales of Glyxambi totaled $215.8 million in the US market.
- Zydus has 428 approvals and continues filing new ANDAs.
These new tablets will be used alongside diet and exercise to manage blood sugar levels in adults with type 2 diabetes. The approval marks a key step in offering a more affordable treatment option for patients. Zydus’s production facility in Ahmedabad, India, will handle the manufacturing of these tablets.
The Glyxambi tablets have already shown strong performance, with annual sales reaching $215.8 million in the United States (as of September 2025, according to IQVIA data). This highlights the continued demand for effective diabetes management solutions.
Zydus Lifesciences has a total of 428 approvals globally and has filed 487 ANDAs since FY 2003-04. This demonstrates their commitment to innovation and expanding access to healthcare.
Zydus’s overall goal is to empower people to live healthier lives. The company employs over 27,000 people worldwide and focuses on developing quality healthcare solutions.
Zydus reported strong financial results, with a 38.12% jump in consolidated net profit to Rs 1,258.60 crore in Q2 FY26, alongside a 18.07% increase in revenue to Rs 6,037.9 crore.
The Zydus share price rose by 0.54% to Rs 942.35 on the BSE.
Ultimately, Zydus Lifesciences’ success reflects a dedication to providing accessible and effective medications for diabetes patients globally.
